# Bulevirtide Linked to Less Decompensation in Chronic Hep D With Cirrhosis

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/aasld/123789) · 2026-11-09 · Medicine
Page: https://themorning.science/story/bulevirtide-linked-to-less-decompensation-in-chronic-hep-d-with-cirrhosis-98621c5bd9c0d189
Kind: research · Impact: medium

## In brief

- In patients with chronic hepatitis delta and cirrhosis, bulevirtide (Hepcludex) treatment was associated with a lower risk of liver decompensation.
- The findings come from a European retrospective study, as reported by MedPage Today from the AASLD meeting coverage.

## Why it matters

Liver decompensation is a major complication of cirrhosis, so an association between bulevirtide and fewer decompensation events is relevant to how clinicians manage this patient group. Because the study is retrospective, it shows an association rather than proof of causation.

## Coverage

- [Bulevirtide Linked to Less Decompensation in Chronic Hep D With Cirrhosis](https://www.medpagetoday.com/meetingcoverage/aasld/123789) — MedPageToday.com - medical news for physicians, 2026-11-09

Tags: hepatitis delta, bulevirtide, cirrhosis, liver decompensation, hepatology

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science